← Back to Search

Nutritional Supplements and Metabolite Intermediates

Mitochondrial Cocktail for Autism Spectrum Disorder (MitoASD Trial)

Phase 1
Waitlist Available
Research Sponsored by Drexel University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (0), 3 and 6 months
Awards & highlights

MitoASD Trial Summary

In this study, 50 children between 3 and 12 years old with formally diagnosed autistic spectrum disorders (ASD) and also having significant mitochondrial dysfunction will be treated for a 3 month period with the Mitochondrial Cocktail, a combination of specific nutritional supplements and metabolite intermediates (including anti-oxidants) and bio-energy substrates. A series of neurological and psychological evaluations will be conducted by trained evaluators/clinicians to evaluate both the severity and the clinical presentation of the ASD/mitochondrial dysfunction with each subject at baseline prior to treatment, after the 3 month treatment and again at 6 months, after another 3 month non-treatment period. In addition, laboratory investigations will be conducted at the same time-points to assess the mitochondrial dysfunction and cellular biomarkers thought to be associated with autistic and mitochondrial disorders. These investigations will include the analysis of samples of blood and cheek/buccal swabs collected from each child to assess select biochemical markers of ASD. The Mitochondrial Cocktail treatment will be administered at home once a day continuously for a total of 3 months. All the children in the study will be treated with the same Mitochondrial Cocktail (an open label study).

Eligible Conditions
  • Autism Spectrum Disorder
  • Mitochondrial Disease

MitoASD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (0), 3 and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (0), 3 and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Executive Function assessed using the Behavior Rating Inventory of Executive Function (BRIEF)
Change in features of Autistic behavior phenotype assessed using the Social Responsiveness Scale (SRS)
Secondary outcome measures
Change in buccal oxidative stress markers and mitochondrial DNA (mtDNA) damage
Changes in mitochondrial enzyme specific activities biochemically evaluated using buccal swab analysis

Side effects data

From 2016 Phase 1 & 2 trial • 54 Patients • NCT02133664
23%
Nausea
15%
Urine odor abnormal
15%
Dyspepsia
12%
Throat irritation
12%
Fatigue
8%
Headache
8%
Urinary tract infection
8%
Incontinence
8%
Adverse drug reaction
4%
Deafness unilateral
4%
Kidney Infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Lipoic Acid and Omega-3 Fatty Acids

MitoASD Trial Design

1Treatment groups
Experimental Treatment
Group I: Mitochondrial CocktailExperimental Treatment1 Intervention
The precise content of the Mitochondrial Cocktail will be: ubiquinol (liquid form, 150 mg/kg subject weight/day carnitine, 50 mg/kg subject weight/day alpha-lipoic acid, 100 mg/ day

Find a Location

Who is running the clinical trial?

Drexel UniversityLead Sponsor
150 Previous Clinical Trials
47,651 Total Patients Enrolled
8 Trials studying Autism Spectrum Disorder
21,009 Patients Enrolled for Autism Spectrum Disorder
Michael J Goldenthal, PhDStudy DirectorDrexel University College of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025